ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) announced its earnings results on Friday. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.21, Zacks reports.
ENDRA Life Sciences Stock Performance
NDRA stock remained flat at $4.47 during midday trading on Friday. The company had a trading volume of 51,812 shares, compared to its average volume of 16,716. The firm has a 50-day simple moving average of $4.85 and a two-hundred day simple moving average of $4.60. ENDRA Life Sciences has a one year low of $2.96 and a one year high of $9.85. The firm has a market cap of $5.68 million, a PE ratio of -0.55 and a beta of -0.05.
Wall Street Analysts Forecast Growth
NDRA has been the subject of several analyst reports. Ascendiant Capital Markets decreased their price objective on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a report on Monday, June 1st. Weiss Ratings upgraded ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $25.00.
About ENDRA Life Sciences
ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.
ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.
Featured Stories
- Five stocks we like better than ENDRA Life Sciences
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
